MiR-146a and miR-155 expression levels in acute graft-versus-host disease incidence

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Atarod, Sadaf ^a   Ahmed, Mohammed Mahid ^a   Lendrem, Clare ^a   Pearce, Kim Frances ^a   Cope, Wei ^a   Norden, Jean ^a   Wang, Xiao Nong ^a   Collin, Matthew ^a   Dickinson, Anne Mary ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; Biological markers; Graft versus host disease; MicroRNAs

Indexed keywords

EID: 84964612038     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00056     Document Type: Article

References (34)

1. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood (2012) 119(20):4786-97. doi: 10.1182/blood-2011-10-387522
2. Shen N, Liang D, Tang Y, de Vries N, Tak P-P. MicroRNAs novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol (2012) 8(12):701-9. doi:10.1038/nrrheum.2012.142
3. Xiao B, Wang Y, Li W, Baker M, Guo J, Corbet K, et al. Plasma microRNA signature as a non-invasive biomarker for acute graft-versus-host disease. Blood (2013) 122(19):3365-75. doi:10.1182/blood-2013-06-510586
4. Stickel N, Prinz G, Pfeifer D, Hasselblatt P, Schmitt-GraeffA, Follo M, et al. MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GvHD. Blood (2014) 124(16):2586-95. doi:10.1182/blood-2014-04-569046
5. Lindsay MA. MicroRNAs and the immune response. Trends Immunol (2008) 29(7):343-51. doi:10.1016/j.it.2008.04.004
6. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther (2008) 10(4):R101. doi:10.1186/ar2493
7. Lu L-F, Boldin MP, Chaudhry A, Lin L-L, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 142(6):914-29. doi:10.1016/j.cell.2010.08.012
8. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 103:12481-6. doi:10.1073/pnas.0605298103
9. Taganov KD, Boldin MP, Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity (2007) 26(2):133-7. doi:10.1016/j.immuni.2007.02.005
10. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, et al. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum (2009) 60(4):1065-75. doi:10.1002/art.24436
11. Stauffer N, Hamadani SM, Heaphy C, Santhanam R, Sandhu S, Costinean S, et al. Regulation of acute graft-versus-host disease by microRNA-155. Exp Transplant (2010) 119(20):4786-97. doi:10.1182/blood-2011-10-387522
12. Tanabe Y, Nishibori T, Su L, Arduini RM, Baker DP, David M. Cutting edge: role of STAT1, STAT3, and STAT5 in αβ responses in T lymphocytes. J Immunol (2005) 174(2):609-13. doi:10.4049/jimmunol.174.2.609
13. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, et al. The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling. Nat Immunol (2013) 14(6):593-602. doi:10.1038/ni.2576
14. Chen S, Smith BAH, Iype J, Prestipino A, Pfeifer D, Grundmann S, et al. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood (2015) 126(1):103-12. doi:10.1182/blood-2014-12-617258
15. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2006) 38(1):27-37. doi:10.1038/ng1679
16. Thompson RC, Herscovitch M, Zhao I, Ford TJ, Gilmore TD. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem (2011) 286(3):1675-82. doi:10.1074/jbc. M110.177063
17. Ghani S, Riemke P, Schönheit J, Lenze D, Stumm J, Hoogenkamp M, et al. Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood (2011) 118(8):2275-84. doi:10.1182/blood-2011-02-335141
18. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant (2005) 11(12):945-56. doi:10.1016/j.bbmt.2005.09.004
19. Viprey VF, Corrias MV, Burchill SA. Identification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling. Anal Biochem (2012) 421(2):566-72. doi:10.1016/j.ab.2011.10.022
20. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2013) 48(S1):S1-37. doi:10.1038/bmt.2012.282
21. Brown H, Prescott R. Applied Mixed Models in Medicine. Second ed. Chichester: J. Wiley & Sons (1999). p. 107-81.
22. Hinton PR. Interaction of factors in the analysis of variance. 3rd ed. Statistics Explained. Hove: Routledge (2014). p. 157-65.
23. Nahid MA, Pauley KM, Satoh M, Chan EKL. MiR-146a is critical for endotoxin-induced tolerance. J Biol Chem (2009) 284(50):34590-9. doi:10.1074/jbc. M109.056317
24. Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol (2010) 40(1):225-31. doi:10.1002/eji.200939381
25. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 4(5):371-80. doi:10.1038/nrc1365
26. Schulte LN, Westermann AJ, Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res (2012) 41(1):542-53. doi:10.1093/nar/gks1030
27. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol (1993) 5(5):794-9. doi:10.1016/0952-7915(93)90139-J
28. Xie LN, Zhou F, Liu XM, Fang Y, Yu Z, Song NX, et al. Serum microRNA155 is increased in patients with acute graft-versus-host disease. Clin Transplant (2014) 28(3):314-23. doi:10.1111/ctr.12314
29. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. MiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med (2011) 208(6):1189-201. doi:10.1084/jem.20101823
30. Luo X, Tsai LM, Shen N, Yu D. Evidence for microRNA-mediated regulation in rheumatic diseases. Ann Rheum Dis (2010) 69(Suppl 1):i30-6. doi:10.1136/ard.2009.117218
31. Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood (2003) 101(1):270-7. doi:10.1182/blood-2002-04-1288
32. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res (2008) 36(Suppl 1):D149-53. doi:10.1093/nar/gkm995
33. Joyce CE, Novina CD. MiR-155 in acute myeloid leukemia: not merely a prognostic marker? J Clin Oncol (2013) 31(17):2219-21. doi:10.1200/JCO.2012.48.3180
34. Rusca N, Monticelli S. MiR-146a in immunity and disease. Mol Biol Int (2011) 2011:1-7. doi:10.4061/2011/437301